We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App





Horiba Presents Comprehensive Range of Hematology, Hemostasis and Clinical Chemistry Analyzers at MEDLAB Middle East

By LabMedica International staff writers
Posted on 24 Jan 2022

Horiba Medical (Kyoto, Japan) presented its comprehensive hematology, hemostasis and clinical chemistry analyzer ranges, as well as its HELO Solution that meets all laboratory configuration needs at MEDLAB Middle East 2022. More...

At the 2022 edition of MEDLAB Middle East, Horiba displayed its Yumizen G Range of five hemostasis analyzers and a comprehensive reagents menu from routine to specialized tests. Also on display was Horiba’s new compact hematology system the Yumizen H550 that provides full walk-away capability to small-mid size laboratories. The Yumizen H550 is a compact hematology system with integrated sample rack auto loading that is designed to provide rapid testing and full hematology diagnosis. It provides the operator with a full walk-away capacity of 40 tubes with continuous loading. Based on proven and innovative technologies, it answers the need for a robust analyzer and requires no user maintenance. Horiba also displayed the Yumizen H2500, its new generation automated hematology analyzer that answers customers expectations of solid and reliable diagnostic technology as well as rapid and consistent results.

The focus at Horiba’s demonstrations at the event was on the company’s global hematology solution, the HELO Solution (HORIBA Evolutive Laboratory Organization). HELO is an innovative design solution covering all the needs of a high throughput automated hematology platform. Flexible and efficient, HELO is the optimum answer to the constant evolution of any laboratory. The HORIBA advanced technologies embedded in the Yumizen H2500/H1500 associated with over 30 years experience in Hematology diagnosis offer the highest analytical performances. Thanks to its data, tube management, waste, blood film and digitalization management capability, HELO not only addresses a lab’s needs, but helps them to optimize TAT, floor space and reagent storage.

Related Links:
Horiba Medical 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Electrolyte Analyzer
BKE-B
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The updated CRC screening guidance adds a stool RNA test and an updated stool DNA test to the menu of preferred options (image credit: Adobe Stock)

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Immunology

view channel
Image: Study design for analysis of monocyte phenotype, function, and metabolism (Gráinne Jameson et al., Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106755)

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.